ストックスクリーナーアプリを入手
424.99
1.07%
-4.61
アフターアワーズ：
426.90
1.91
+0.45%
Vertex Pharmaceuticals Inc (VRTX) 最新ニュース
Final Trades: Vertex Pharma, Palantir, Wynn Resorts and Microsoft - CNBC
Vertex Pharmaceuticals Incorporated (VRTX) Surged On a Recovery in Investor Sentiment - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Vertex Pharmaceuticals Incorporated Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now - Yahoo Finance
4 No-Brainer Stocks to Buy Right Now - The Motley Fool
Unpacking Q1 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks - Yahoo Finance
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2025 Earnings Call Transcript - Insider Monkey
Leerink Partners Downgrades Vertex Pharmaceuticals (XTRA:VX1) - Nasdaq
Vertex Pharmaceuticals (VRTX) Faces Downgrade After Q1 Revenue Miss - GuruFocus
Vertex Pharma extends selloff as Wolfe downgrades after Q1 miss - MSN
Vertex Pharma stock downgraded at Wolfe (VRTX:NASDAQ) - Seeking Alpha
Cystic fibrosis Market: Epidemiology, Therapies, Companies, - openPR.com
VRTX Stock Down as Q1 Sales of New Drugs Miss Expectations - TradingView
Leerink Partners Downgrades Vertex Pharmaceuticals (BIT:1VRTX) - Nasdaq
Vertex Pharmaceuticals (VRTX) Sees Target Price Increase to $499 by Barclays | VRTX Stock News - GuruFocus
Leerink Partners Downgrades Vertex Pharmaceuticals (WBAG:VRTX) - Nasdaq
Wolfe Research Downgrades Vertex Pharmaceuticals to Peer Perform From Outperform - marketscreener.com
Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip - MSN
Vertex Pharmaceuticals (VRTX) Downgraded Amid Revenue Concerns | VRTX Stock News - GuruFocus
Vertex stock rating downgraded at Wolfe Research By Investing.com - Investing.com UK
Vertex On Track To Significantly Improve Revenue And Earnings By 2030 (NASDAQ:VRTX) - Seeking Alpha
Leerink Partners Downgrades Vertex Pharmaceuticals (LSE:0QZU) - Nasdaq
Vertex Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks
Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches - insights.citeline.com
Vertex Pharmaceuticals (VRTX) Analyst Rating Update | VRTX Stock News - GuruFocus
Goldman Sachs Raises Price Target for Vertex Pharmaceuticals (VRTX) | VRTX Stock News - GuruFocus
Big-Name Biotech Dives 10% On A Series Of Setbacks - Investor's Business Daily
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Why Did Vertex Pharmaceuticals Stock Fall On Tuesday? - Benzinga
Jim Cramer on Vertex (VRTX): “Vertex’s Painkiller Could Be Revolutionary” - Insider Monkey
Tuesday Sector Laggards: Healthcare, Industrial - Nasdaq
Vertex, with new launches gaining steam, boosts revenue forecast despite Trikafta dilemma in Russia - Fierce Pharma
Vertex to manufacture gene therapies in New Hampshire - The Business Journals
Vertex Pharmaceuticals (NasdaqGS:VRTX) Raises Guidance Despite Intangible Asset Impairment Charge - Yahoo Finance
Vertex pauses Moderna-partnered cystic fibrosis trial, takes $379M hit tied to separate program - Fierce Biotech
Vertex Pharmaceuticals (VRTX) Price Target Raised by Morgan Stanley | VRTX Stock News - GuruFocus
Why Vertex Pharmaceuticals Stock Is Down Sharply - Barron's
Vertex Pharmaceuticals (VRTX) Stock Drops 12% Amid Rising Costs and IP Issues - GuruFocus
Relative Strength Alert For Vertex Pharmaceuticals - Nasdaq
VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened - TradingView
Top Stock Movers Now: Vertex, DoorDash, Constellation Energy, and More - Investopedia
Cantor Fitzgerald maintains Vertex stock Overweight with $535 target By Investing.com - Investing.com UK
Bernstein raises Vertex stock target to $462 on market resilience By Investing.com - Investing.com UK
Stock Movers: Palantir, Vertex Pharmaceuticals, DoorDash - Bloomberg.com
Stifel holds Vertex stock with $194 target post-Q1 results - Investing.com
Why Vertex Pharmaceuticals Stock Is Sinking Today - MSN
Vertex Pharmaceuticals (VRTX) Stock Declines After Earnings Miss - GuruFocus
Vertex Pharmaceuticals Stock Sinks as Costs Soar - Investopedia
2 Pharma Stocks Staging Big Post-Earnings Moves - Schaeffer's Investment Research
Vertex Pharmaceuticals (VRTX) Price Target Raised by JP Morgan | VRTX Stock News - GuruFocus
Despite Q1 miss, pain drug launch and new CF therapy drive Vertex growth - The Pharma Letter
Vertex Pharmaceuticals (VRTX) Receives Reiterated Overweight Rat - GuruFocus
Vertex Pharmaceuticals (VRTX) Target Price Lowered by Scotiabank Analyst | VRTX Stock News - GuruFocus
Vertex Pharmaceuticals (VRTX) Receives Reiterated Overweight Rating from Cantor Fitzgerald | VRTX Stock News - GuruFocus
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $621 From $617 - marketscreener.com
Vertex Pharmaceuticals (VRTX) Sees Price Target Increase Amid Adjusted Revenue Guidance | VRTX Stock News - GuruFocus
Rising Costs Weigh on Vertex Q1 Earnings - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Rating Reiterated at Hold by Needh - GuruFocus
RBC Capital Adjusts Price Target for Vertex Pharmaceuticals (VRT - GuruFocus
Barclays Adjusts Vertex Pharmaceuticals Price Target to $499 From $467, Maintains Equal Weight Rating - marketscreener.com
Vertex Pharmaceuticals (VRTX) Rating Reiterated at Hold by Needham | VRTX Stock News - GuruFocus
RBC Capital Adjusts Price Target for Vertex Pharmaceuticals (VRTX) | VRTX Stock News - GuruFocus
RBC Raises Price Target on Vertex Pharmaceuticals to $423 From $420, Keeps Sector Perform Rating - marketscreener.com
Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
3.63%
大文字化:
|
ボリューム (24 時間):